Compare AbCellera Biologics Inc (ABCL) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Cigna Corp — how do they compare? AbCellera Biologics Inc trades at $8.9 (market cap $2.85B), while Cigna Corp trades at $273 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 25.8× AbCellera Biologics Inc's market cap, and Cigna Corp pays a 2.24% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CI | |
|---|---|---|
Market Cap | $2.85B | $73.56B |
Sector | Health | Health |
52-Week High | $9.76 | $311.00 |
52-Week Low | $2.78 | $244.41 |
Enterprise Value | $2.45B | $98.27B |
Dividend Yield | — | 2.24% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
